+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Elastography, a sensitive tool for the evaluation of neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma



Elastography, a sensitive tool for the evaluation of neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma



Oncology Letters 8(4): 1652-1656



The aim of the present study was to evaluate tumor stiffness by ultrasound elastography, which has the potential to provide additional information that is useful in predicting the response to neoadjuvant chemotherapy (NACT) in high-grade serous ovarian carcinoma (HGSC) patients. In total, 32 patients with International Federation of Gynecology and Obstetrics stage III and IV epithelial ovarian cancer treated with NACT underwent transvaginal and transabdominal sonography, followed by elastography and finally, by interval cytoreductive surgery. Histopathological analysis revealed 24 (75%) HGSCs. The mean elasticity score was statistically higher for the post-NACT lesions than for the pre-NACT lesions (3.13±0.57 vs. 2.04±0.51, respectively; P<0.001). The median elasticity score for the pre-NACT lesions on the four-point scale was 2, and the score for the post-NACT lesions was 4. Cases of post-NACT with scores of 3 and 4 had a higher optimal cytoreduction rate than cases with scores of 1 and 2 (93.8 vs. 25.0%, respectively; P<0.001). When the post-NACT elasticity scores of 3 and 4 were used for the prediction of optimal cytoreduction, elastography exhibited 88.2% sensitivity, 85.7% specificity, a 93.8% positive predictive value, a 75.0% negative predictive value and 87.5% accuracy. The results of the current study suggested that elastography is a sensitive tool for the evaluation of NACT in patients with HGSC and that it may aid gynecologists in choosing the optimal cytoreduction.

(PDF emailed within 0-6 h: $19.90)

Accession: 052914653

Download citation: RISBibTeXText

PMID: 25202385

DOI: 10.3892/ol.2014.2346


Related references

Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma. International Journal of Gynecological Cancer, 2017

Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma. International Journal of Gynecological Cancer 27(4): 708-713, 2018

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. Molecular Cancer Research 16(5): 813-824, 2018

Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research 44(9): 1808-1816, 2018

Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma. Gynecologic Oncology 151(2): 264-268, 2018

Type-specific response to neoadjuvant chemotherapy: ovarian high-grade serous carcinoma versus colorectal mucinous carcinoma. Journal of Obstetrics and Gynaecology Canada 34(7): 678-682, 2014

A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. Histopathology 71(5): 736-742, 2017

Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma. Clinical Cancer Research 22(12): 3025-3036, 2018

Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes. Surgical Pathology Clinics 12(2): 515-528, 2019

Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience. Yonsei Medical Journal 59(8): 930-936, 2018

Measuring response to neoadjuvant chemotherapy in high-grade serous tubo-ovarian carcinoma: an analysis of the correlation between CT imaging and chemotherapy response score. International Journal of Gynecological Cancer 2019, 2019

Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. Journal of Clinical Oncology 33(22): 2457-2463, 2015

Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results. International Journal of Gynecological Cancer 2019, 2019

Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. American Journal of Surgical Pathology 36(3): 368-375, 2012

Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708). Bmc Cancer 19(1): 341, 2019